Cancer patients in India may soon see a sharp drop in the price of some of the country’s most expensive drugs, as the government moves to impose a 30% cap on trade profit margins above distributors’ costs. According to sources at the Department of Pharmaceuticals, the measure will cover expensive cancer drugs, including some patented medicines, and could reduce their retail prices by up to 70%.
The decision is part of the government’s effort to curb excessive markups in the cancer drug market. It builds on a 2019 pilot programme that capped trade margins for 42 cancer medicines. The new move specifically targets expensive drugs, where even a relatively large margin translates into a substantial increase in the price patients pay.
For cancer patients and their families, the measure could directly reduce the amount they pay for some of the most expensive drugs. A reduction of up to 70% in the maximum retail price could translate into significant savings, particularly for patients who need prolonged treatment with costly medicines.
However, the actual outcome will depend on which drugs make the final list and how much of the reduction in existing trade margins is ultimately passed on to patients.
A committee headed by the Director General of Health Services is currently drawing up the list of drugs that will come under the new rules. The measure is expected to take effect within ten days.
The drugs under consideration must be approved for cancer treatment in India, be frequently used and meet the central criterion of a high price. An official at the Department of Pharmaceuticals explained that being expensive is an important criterion for selecting a drug.
Extending the 30% cap to cheaper drugs could discourage companies from selling them, as the regulated margin may not adequately cover marketing and distribution costs. For this reason, the government aims to target drugs where the impact on patients is likely to be greatest, avoiding an across-the-board cap that could disrupt the supply and distribution of lower-priced medicines.
If implemented as planned, the measure could significantly change the pricing of some of the most expensive cancer treatments available in India. Total savings for patients are estimated to potentially reach hundreds of crores each year, although the final benefit remains uncertain until the drug list is finalised.
The story, by Indian Express journalist Anonna Dutt, focuses on health and the financial burden that noncommunicable diseases place on households.
Comments